Pavmed Series Z Stock Last Dividend Paid

PAVMZ Stock

USD 0.01 0.0001 0.66%

PAVmed Series Z fundamentals help investors to digest information that contributes to PAVmed Series' financial success or failures. It also enables traders to predict the movement of PAVmed Stock. The fundamental analysis module provides a way to measure PAVmed Series' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PAVmed Series stock.

Other Current Assets Capital Surpluse

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

PAVmed Series Z Company Last Dividend Paid Analysis

PAVmed Series' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

PAVmed Last Dividend Paid Driver Correlations

Understanding the fundamental principles of building solid financial models for PAVmed Series is extremely important. It helps to project a fair market value of PAVmed Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since PAVmed Series' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PAVmed Series' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PAVmed Series' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Property Plant Equipment	Long Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Short Long Term Debt	Capital Stock	Short Term Debt	Short Term Investments	Net Tangible Assets	Current Deferred Revenue	Net Receivables	Good Will	Intangible Assets
Total Assets		0.3	-0.58	-0.66	0.75	0.45	1.0	0.79	0.78	0.7	-0.66	-0.16	0.81	0.61	0.82	0.67	0.82	0.81	0.21	0.78	0.87	0.21	-0.43
Total Stockholder Equity	0.3		-0.94	0.51	-0.28	-0.7	0.38	0.47	0.1	-0.26	0.18	0.72	0.79	0.93	-0.23	-0.44	-0.23	-0.26	-0.74	-0.29	0.38	-0.74	0.7
Net Debt	-0.58	-0.94		-0.22	0.0	0.45	-0.65	-0.6	-0.31	0.01	0.04	-0.52	-0.92	-1.0	-0.08	0.17	-0.09	-0.04	0.52	-0.03	-0.65	0.52	-0.45
Retained Earnings	-0.66	0.51	-0.22		-0.92	-0.97	-0.6	-0.35	-0.66	-0.86	0.76	0.74	-0.11	0.18	-0.91	-0.96	-0.9	-0.92	-0.77	-0.91	-0.5	-0.77	0.92
Capital Surpluse	0.75	-0.28	0.0	-0.92		0.86	0.72	0.57	0.88	0.96	-0.91	-0.59	0.34	0.02	0.84	0.95	0.84	0.82	0.58	0.8	0.57	0.58	-0.72
Total Liab	0.45	-0.7	0.45	-0.97	0.86		0.39	0.2	0.56	0.8	-0.72	-0.8	-0.12	-0.42	0.78	0.93	0.78	0.81	0.8	0.8	0.27	0.8	-0.95
Total Current Assets	1.0	0.38	-0.65	-0.6	0.72	0.39		0.79	0.78	0.67	-0.64	-0.13	0.85	0.67	0.77	0.62	0.77	0.75	0.15	0.73	0.9	0.15	-0.35
Common Stock	0.79	0.47	-0.6	-0.35	0.57	0.2	0.79		0.8	0.57	-0.61	0.25	0.85	0.6	0.48	0.45	0.48	0.52	-0.26	0.38	0.47	-0.26	-0.16
Accounts Payable	0.78	0.1	-0.31	-0.66	0.88	0.56	0.78	0.8		0.86	-0.92	-0.21	0.61	0.31	0.64	0.73	0.64	0.62	0.19	0.56	0.57	0.19	-0.39
Property Plant Equipment	0.7	-0.26	0.01	-0.86	0.96	0.8	0.67	0.57	0.86		-0.88	-0.54	0.32	0.01	0.78	0.93	0.78	0.76	0.54	0.74	0.53	0.54	-0.67
Long Term Debt	-0.66	0.18	0.04	0.76	-0.91	-0.72	-0.64	-0.61	-0.92	-0.88		0.41	-0.37	-0.05	-0.67	-0.8	-0.67	-0.65	-0.41	-0.63	-0.46	-0.41	0.54
Long Term Debt Total	-0.16	0.72	-0.52	0.74	-0.59	-0.8	-0.13	0.25	-0.21	-0.54	0.41		0.35	0.48	-0.48	-0.63	-0.48	-0.49	-0.8	-0.55	-0.25	-0.8	0.74
Net Invested Capital	0.81	0.79	-0.92	-0.11	0.34	-0.12	0.85	0.85	0.61	0.32	-0.37	0.35		0.92	0.36	0.17	0.36	0.34	-0.36	0.28	0.72	-0.36	0.15
Net Working Capital	0.61	0.93	-1.0	0.18	0.02	-0.42	0.67	0.6	0.31	0.01	-0.05	0.48	0.92		0.11	-0.15	0.11	0.07	-0.5	0.06	0.68	-0.5	0.42
Short Long Term Debt	0.82	-0.23	-0.08	-0.91	0.84	0.78	0.77	0.48	0.64	0.78	-0.67	-0.48	0.36	0.11		0.9	1.0	0.97	0.68	0.99	0.68	0.68	-0.78
Capital Stock	0.67	-0.44	0.17	-0.96	0.95	0.93	0.62	0.45	0.73	0.93	-0.8	-0.63	0.17	-0.15	0.9		0.9	0.88	0.71	0.87	0.46	0.71	-0.85
Short Term Debt	0.82	-0.23	-0.09	-0.9	0.84	0.78	0.77	0.48	0.64	0.78	-0.67	-0.48	0.36	0.11	1.0	0.9		0.97	0.68	0.99	0.68	0.68	-0.78
Short Term Investments	0.81	-0.26	-0.04	-0.92	0.82	0.81	0.75	0.52	0.62	0.76	-0.65	-0.49	0.34	0.07	0.97	0.88	0.97		0.6	0.97	0.6	0.6	-0.86
Net Tangible Assets	0.21	-0.74	0.52	-0.77	0.58	0.8	0.15	-0.26	0.19	0.54	-0.41	-0.8	-0.36	-0.5	0.68	0.71	0.68	0.6		0.73	0.27	1.0	-0.75
Current Deferred Revenue	0.78	-0.29	-0.03	-0.91	0.8	0.8	0.73	0.38	0.56	0.74	-0.63	-0.55	0.28	0.06	0.99	0.87	0.99	0.97	0.73		0.68	0.73	-0.82
Net Receivables	0.87	0.38	-0.65	-0.5	0.57	0.27	0.9	0.47	0.57	0.53	-0.46	-0.25	0.72	0.68	0.68	0.46	0.68	0.6	0.27	0.68		0.27	-0.22
Good Will	0.21	-0.74	0.52	-0.77	0.58	0.8	0.15	-0.26	0.19	0.54	-0.41	-0.8	-0.36	-0.5	0.68	0.71	0.68	0.6	1.0	0.73	0.27		-0.75
Intangible Assets	-0.43	0.7	-0.45	0.92	-0.72	-0.95	-0.35	-0.16	-0.39	-0.67	0.54	0.74	0.15	0.42	-0.78	-0.85	-0.78	-0.86	-0.75	-0.82	-0.22	-0.75

Click cells to compare fundamentals

Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.

Competition

Predict PAVmed Series

PAVmed Dividends Paid

Dividends Paid

10.73 Billion

At this time, PAVmed Series' Dividends Paid is fairly stable compared to the past year.

Based on the recorded statements, PAVmed Series Z has a Last Dividend Paid of 0.0. This indicator is about the same for the Health Care Equipment & Supplies average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

PAVmed Last Dividend Paid Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PAVmed Series' direct or indirect competition against its Last Dividend Paid to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PAVmed Series could also be used in its relative valuation, which is a method of valuing PAVmed Series by comparing valuation metrics of similar companies.

PAVmed Series is currently under evaluation in last dividend paid category among its peers.

PAVmed Series Current Valuation Drivers

We derive many important indicators used in calculating different scores of PAVmed Series from analyzing PAVmed Series' financial statements. These drivers represent accounts that assess PAVmed Series' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PAVmed Series' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	30.8M	21.4M	100.6M	42.8M	29.8M	57.7M
Enterprise Value	31.3M	21.1M	98.3M	39.6M	58.9M	62.0M

PAVmed Fundamentals

	Return On Equity	-13.58
	Return On Asset	-0.8
	Operating Margin	(13.98) %
	Number Of Shares Shorted	46.01 K
	Revenue	2.45 M
	EBITDA	(75.74 M)
	Net Income	(64.17 M)
	Total Debt	48.73 M
	Book Value Per Share	(6.62) X
	Cash Flow From Operations	(52.04 M)
	Number Of Employees	107
	Beta	0.69
	Total Asset	33.12 M
	Retained Earnings	(294.43 M)
	Working Capital	(29.68 M)
	Net Asset	33.12 M

About PAVmed Series Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PAVmed Series Z's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PAVmed Series using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PAVmed Series Z based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC